The current state of proteomics in GI oncology.
Proteomics refers to the study of the entire set of proteins in a given cell or tissue. With the extensive development of protein separation, mass spectrometry, and bioinformatics technologies, clinical proteomics has shown its potential as a powerful approach for biomarker discovery, particularly in the area of oncology. More than 130 exploratory studies have defined candidate markers in serum, gastrointestinal (GI) fluids, or cancer tissue. In this article, we introduce the commonly adopted proteomic technologies and describe results of a comprehensive review of studies that have applied these technologies to GI oncology, with a particular emphasis on developments in the last 3 years. We discuss reasons why the more than 130 studies to date have had little discernible clinical impact, and we outline steps that may allow proteomics to realize its promise for early detection of disease, monitoring of disease recurrence, and identification of targets for individualized therapy.
Lin
Ying
Y
Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA 30912, USA.
Dynan
William S
WS
Lee
Jeffrey R
JR
Zhu
Zhao-Hua
ZH
Schade
Robert R
RR
D014408:Biomarkers, Tumor / Q000378:metabolism*; D005762:Gastroenterology / Q000639:trends*; D005770:Gastrointestinal Neoplasms / Q000378:metabolism*; D006801:Humans; D008495:Medical Oncology / Q000639:trends*; D040901:Proteomics / Q000639:trends*
D014408:Biomarkers, Tumor